Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Bioentrepreneur
  • Published:

Corporate venture capital and Cambridge

Nature Biotechnology volume 32, pages 975–978 (2014)Cite this article

Subjects

A novel route to entrepreneurship at the University of Cambridge.

Access through your institution
Buy or subscribe

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Timeline for CVC arms of big pharma.
Figure 2: Milestones that trigger the initiation of a spin-out venture.

References

  1. Pammolli, F., Magazzini, L. & Riccaboni, M. Nat. Rev. Drug Discov. 10, 428–438 (2011).

    Article  CAS  Google Scholar 

  2. Hudson, J. & Khazragui, H.F. Drug Discov. Today 18, 610–613 (2013).

    Article  Google Scholar 

  3. Hörig, H., Marincola, E. & Marincola, F.M. et al. Nat. Med. 11, 705–708 (2005).

    Article  Google Scholar 

Download references

Acknowledgements

The authors would like to thank the academic, industry and venture capital scientists who generously gave their time to participate in iterative interviews during this research. Thanks also to N. Reynolds for administrative support.

Author information

Authors and Affiliations

  1. Margaret G. McCammon was business development consultant, University of Cambridge Judge Business School, Cambridge, UK, and is currently portfolio manager for entrepreneurship and innovation, Michigan Economic Development Corporation, Lansing, Michigan, USA.,

    Margaret G McCammon

  2. Edwina Pio is professor of diversity, Auckland University of Technology School of Business and Law, Auckland, New Zealand.,

    Edwina Pio

  3. Shima Barakat is research and teaching fellow, director of EnterpriseWISE and ETECH Projects, Centre for Entrepreneurial Learning at the University of Cambridge Judge Business School, Cambridge, UK.,

    Shima Barakat

  4. Shailendra Vyakarnam is director, Centre for Entrepreneurial Learning, University of Cambridge Judge Business School, Cambridge, UK.,

    Shailendra Vyakarnam

Authors
  1. Margaret G McCammon
    View author publications

    Search author on:PubMed Google Scholar

  2. Edwina Pio
    View author publications

    Search author on:PubMed Google Scholar

  3. Shima Barakat
    View author publications

    Search author on:PubMed Google Scholar

  4. Shailendra Vyakarnam
    View author publications

    Search author on:PubMed Google Scholar

Corresponding authors

Correspondence to Margaret G McCammon, Edwina Pio, Shima Barakat or Shailendra Vyakarnam.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

McCammon, M., Pio, E., Barakat, S. et al. Corporate venture capital and Cambridge. Nat Biotechnol 32, 975–978 (2014). https://doi.org/10.1038/nbt.3029

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/nbt.3029

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research